Search research articles
Contact Us
Filters
Showing results (41-50 of 91) with videos related to
Page
of 10
Sort By:
NPJ Precision Oncology
|
March 1, 2026
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors
Gerald Falchook, Camila Braganca Xavier, David Van Veenhuyzen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2023
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients
Cloud P Paweletz, Grace A Heavey, Yanan Kuang, et al.
Frontiers in Oncology
|
September 13, 2023
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer
Robert Hsu, Denaly Chen, Bing Xia, et al.
Cancer
|
October 4, 2019
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108
Peter H O'Donnell, Hendrick Tobias Arkenau, Srikala S Sridhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2023
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, et al.
The New England Journal of Medicine
|
December 22, 2022
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated <i>KRAS</i> G12C
Rona Yaeger, Jared Weiss, Meredith S Pelster, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 5, 2023
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial
Edward B Garon, Alexander I Spira, Sarah B Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2021
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
George D Demetri, Jason J Luke, Antoine Hollebecque, et al.
Clinical Lung Cancer
|
November 21, 2021
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
Misako Nagasaka, Vijendra Singh, Yasmine Baca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 23, 2024
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Aditya Bardia, Ian E Krop, Takahiro Kogawa, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 91) with videos related to
Sort By:
Page
of 10
NPJ Precision Oncology
|
March 1, 2026
A first-in-human phase 1 study of the SHP2 inhibitor BBP-398 in patients with advanced solid tumors
Gerald Falchook, Camila Braganca Xavier, David Van Veenhuyzen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 6, 2023
Early Changes in Circulating Cell-Free KRAS G12C Predict Response to Adagrasib in KRAS Mutant Non-Small Cell Lung Cancer Patients
Cloud P Paweletz, Grace A Heavey, Yanan Kuang, et al.
Frontiers in Oncology
|
September 13, 2023
Impact of gender and mutational differences in hormone receptor expressing non-small cell lung cancer
Robert Hsu, Denaly Chen, Bing Xia, et al.
Cancer
|
October 4, 2019
Patient-reported outcomes and inflammatory biomarkers in patients with locally advanced/metastatic urothelial carcinoma treated with durvalumab in phase 1/2 dose-escalation study 1108
Peter H O'Donnell, Hendrick Tobias Arkenau, Srikala S Sridhar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 29, 2023
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions
Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, et al.
The New England Journal of Medicine
|
December 22, 2022
Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated <i>KRAS</i> G12C
Rona Yaeger, Jared Weiss, Meredith S Pelster, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
May 5, 2023
Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial
Edward B Garon, Alexander I Spira, Sarah B Goldberg, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 6, 2021
First-in-Human Phase I Study of ABBV-085, an Antibody-Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors
George D Demetri, Jason J Luke, Antoine Hollebecque, et al.
Clinical Lung Cancer
|
November 21, 2021
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
Misako Nagasaka, Vijendra Singh, Yasmine Baca, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 23, 2024
Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study
Aditya Bardia, Ian E Krop, Takahiro Kogawa, et al.
Page
of 10